Transdermal delivery of calcium channel blockers for hypertension

Expert Opinion on Drug Delivery

Volumn 10, Issue 8, 2013, Pages 1137-1153

  Ahad, Abdul ^a   Al Jenoobi, Fahad I ^a   Al Mohizea, Abdullah M ^a   Aqil, Mohd ^b   Kohli, Kanchan ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b HAMDARD UNIVERSITY   (India)

Author keywords

Antihypertensive agent; Calcium channel blockers; Transdermal delivery; Transdermal therapeutic system

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; FELODIPINE; ISRADIPINE; LACIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NITRENDIPINE; VERAPAMIL;

ANGINA PECTORIS; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CONSTIPATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG RELEASE; FIRST PASS EFFECT; FLUSHING; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; MAXIMUM PLASMA CONCENTRATION; MICROEMULSION; NONHUMAN; REVIEW; SIDE EFFECT; SKIN ABSORPTION; SKIN PENETRATION; SKIN PERMEABILITY; STEADY STATE; SUPRAVENTRICULAR TACHYCARDIA; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; SKIN; SKIN ABSORPTION;

EID: 84880569339     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2013.783562     Document Type: Review

References (109)

1. Chuong CM, Nickoloff BJ, Elias PM, et al. What is the 'true' function of skin Exp Dermatol 2002;11:159-87
2. Menon GK. New insights into skin structure: scratching the surface. Adv Drug Deliv Rev 2002;54:S3-17
3. Wertz PW. Lipids and barrier function of the skin. Acta Derm Venereol 2002;208:7-11
4. Madison KC. Barrier function of the skin: "la raison d'être" of the epidermis. J Invest Dermatol 2003;121:231-41 (Pubitemid 36969895)
5. Elias PM. Stratum corneum defensive functions: an integrated view. J Invest Dermatol 2005;125:183-200 (Pubitemid 41648149)
6. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol 2008;26:1261-8
7. Aqil M, Sultana Y, Ali A. Transdermal delivery of beta-blockers. Expert Opin Drug Deliv 2006;3:405-18 . Review article demonstrates the transdermal research on various b-blockers.
8. Advances in the transdermal drug delivery market: market size, leading players, therapeutic focus and innovative technologies, in: business Insights. 2010. Available from: http://www. marketresearch.com/Business-Insightsv893/ Advances-Transdermal-Drug-Delivery-size-2890473/
9. Ahad A, Aqil M, Kohli K, et al. Chemical penetration enhancers: a patent review. Expert Opin Ther Pat 2009;19:969-88 . An excellent review, demonstrates patent status of various chemical permeation enhancer for transdermal use.
10. Ahad A, Aqil M, Kohli K, et al. Transdermal drug delivery: the inherent challenges and technological advancements. Asian J Pharm Sci 2010;5:276-88 . Demonstrates various novel transdermal penetration enhancement technologies.
11. Ahad A, Aqil M, Kohli K, et al. Interactions between novel terpenes and main components of rat and human skin: mechanistic view for transdermal delivery of propranolol hydrochloride. Curr Drug Deliv 2011;8:213-24 . Indicates the effectiveness of various novel terpenes on skin delivery of antihypertensive drug.
12. Ahad A, Aqil M, Kohli K, et al. Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action. Drug Dev Ind Pharm 2011;37:583-96 . Indicates the effectiveness of various novel terpenes on skin delivery of lipophilic drug.
13. Campbell N, Young ER, Drouin D, et al. A framework for discussion on how to improve prevention, management, and control of hypertension in Canada. Can J Cardiol 2012;28:262-9
14. Ralston RA, Lee JH, Truby H, et al. A systematic review and meta-analysis of elevated blood pressure and consumption of dairy foods. J Hum Hypertens 2012;26:3-13
15. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004;22:11-19 (Pubitemid 38293521)
16. Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol 2006;22:553-5 (Pubitemid 44044209)
17. Zweifler AJ, Esler M. Factors influencing the choice of antihypertensive agents. Postgrad Med 1976;60:81-5
18. Epstein BJ, Vogel K, Palmer BF. Dihydropyridine calcium channel antagonists in the management of hypertension. Drugs 2007;67:1309-27 (Pubitemid 46879096)
19. Schwartz A, Triggle DJ. Cellular action of calcium channel blocking drugs. Annu Rev Med 1984;35:325-39
20. Nordlander M, Abrahamsson T, Akerblom B, et al. Vascular versus myocardial selectivity of dihydropyridine calcium antagonists as studied in vivo and in vitro. Pharmacol Toxicol 1995;76:56-62
21. Sweetman SC. Martindale: the complete drug reference. Pharmaceutical Press, London, UK; 2007
22. Thomas BJ, Finnin BC. The transdermal revolution. Drug Discov Today 2004;9(16):697-703 (Pubitemid 39070282)
23. Keleb E, Sharma RK, Mosa EB, et al. Transdermal drug delivery system-design and evaluation. Int J Adv Pharm Sci 2010;1:201-11
24. Talbert RL, Bussey HI. Update on calcium-channel blocking agents. Clin Pharm 1983;2:403-16 (Pubitemid 13002743)
25. Nayler WG. Calcium antagonists: past, present and future-a personal view. J Clin Basic Cardiol 1999;2:155-61 (Pubitemid 30006393)
26. Ram CV, Fenves A. Clinical pharmacology of antihypertensive drugs. Cardiol Clin 2002;20:265-80 (Pubitemid 34803328)
27. Squillante E, Needham T, Zia H. Solubility and in vitro transdermal permeation of nifedipine. Int J Pharm 1997;159:171-80 (Pubitemid 28055852)
28. Squillante E, Maniar A, Needham T, et al. Optimization of in vitro nifedipine penetration enhancement through hairless mouse skin. Int J Pharm 1998;169:143-54 (Pubitemid 28345250)
29. McDaid DM, Deasy PB. An investigation into the transdermal delivery of nifedipine. Pharm Acta Helv 1996;71:253-8 (Pubitemid 26358938)
30. Squillante E, Needham T, Maniar A, et al. Codiffusion of propylene glycol and dimethyl isosorbide in hairless mouse skin. Eur J Pharm Biopharm 1998;46:265-71 (Pubitemid 29057672)
31. Manvir A, Rana AC, Nimrata S, et al. Elastic liposome mediated transdermal delivery of an anti-hypertensive agent: nifedipine. J Drug Deliv Ther 2012;2:55-60
32. Thacharodi D, Rao KP. Transdermal absorption of nifedipine from microemulsion of lipophilic skin penetration enhancers. Int J Pharm 1994;111:235-40 (Pubitemid 24292901)
33. Boltri L, Morel S, Trotta M, et al. In vitro transdermal permeation of nifedipine from thickened microemulsions. J Pharm Belg 1994;49:315-20 (Pubitemid 24303784)
34. Graham DJ, Dow RJ, Hall DJ, et al. The metabolism and pharmacokinetics of nicardipine hydrochloride in man. Br J Clin Pharmacol 1985;20:23S-8S (Pubitemid 16218531)
35. Dow RJ, Graham DJ. A review of the human metabolism and pharmacokinetics of nicardipine hydrochloride. Br J Clin Pharmacol 1986;22:195S-202S (Pubitemid 17087984)
36. Whiting RL, Dow RJ, Graham DJ. An overview of the pharmacology and pharmacokinetics of nicardipine. Angiology 1990;41:987-91
37. Krishnaiah YS, Satyanarayana V, Karthikeyan RS. Effect of the solvent system on the in vitro permeability of nicardipine hydrochloride through excised rat epidermis. J Pharm Pharm Sci 2002;5:123-30 . indicates the efficacy of an antihypertensive drug applied with a transdermal therapeutic system.
38. Krishnaiah YS, Satyanarayana V, Bhaskar P. Influence of limonene on the bioavailability of nicardipine hydrochloride from membrane-moderated transdermal therapeutic systems in human volunteers. Int J Pharm 2002;247:91-102 (Pubitemid 35341141)
39. Krishnaiah YS, Satyanarayana V, Karthikeyan RS. Penetration enhancing effect of menthol on the percutaneous flux of nicardipine hydrochloride through excised rat epidermis from hydroxypropyl cellulose gels. Pharm Dev Technol 2002;7:305-15 . Shows the efficacy of an antihypertensive drug applied with a transdermal therapeutic system. (Pubitemid 34983122)
40. Krishnaiah YS, Satyanarayana V, Bhaskar P. Influence of menthol and pressure-sensitive adhesives on the in vivo performance of membrane-moderated transdermal therapeutic system of nicardipine hydrochloride in human volunteers. Eur J Pharm Biopharm 2003;55:329-37 (Pubitemid 36561560)
41. Krishnaiah YS, Satyanarayana V, Bhaskar P. Enhanced percutaneous permeability of nicardipine hydrochloride by carvone across the rat abdominal skin. Drug Dev Ind Pharm 2003;29:191-202 (Pubitemid 36292942)
42. Akhtar N, Ahad A, Khar RK, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat 2011;21:561-76 . An excellent review demonstrates the role of P-glycoprotein inhibitors in various classes of drugs.
43. Aqil M, Ahad A, Sultana Y, et al. Status of terpenes as skin penetration enhancers. Drug Discov Today 2007;12:1061-7 . An excellent review on the utility of terpenes as permeation enhancers for transdermal drug delivery. (Pubitemid 350180560)
44. Hassan N, Ahad A, Ali M, et al. Chemical permeation enhancers for transbuccal drug delivery. Expert Opin Drug Deliv 2010;7:97-112 . An excellent review on the application of various chemical permeation enhancers for transbuccal drug delivery.
45. Krishnaiah YS, Satyanarayana V, Bhaskar P. Formulation and in vivo evaluation of membrane-moderated transdermal therapeutic systems of nicardipine hydrochloride using carvone as a penetration enhancer. Drug Deliv 2003;10:101-9 (Pubitemid 36588511)
46. Kavitha K, Kumar PD. Development of transdermal patches of nicardipine hydrochloride: an attempt to improve bioavailability. Int J Res Pharma Biomed Sci 2011;1:285-93
47. Aboofazeli R, Zia H, Needham TE. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement. Drug Deliv 2002;9:239-47 (Pubitemid 35397026)
48. Wu PC, Lin YH, Chang JS, et al. The effect of component of microemulsion for transdermal delivery of nicardipine hydrochloride. Drug Dev Ind Pharm 2010;36:1398-403
49. Kolli CS, Banga AK. Characterization of solid maltose microneedles and their use for transdermal delivery. Pharm Res 2008;25:104-13
50. Kann J, Krol GJ, Raemsch KD, et al. Bioequivalence and metabolism of nitrendipine administered orally to healthy volunteers. J Cardiovasc Pharmacol 1984;6:S968-73 (Pubitemid 15085413)
51. Goa KL, Sorkin EM. Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987;33:123-55 (Pubitemid 17021191)
52. Gannu R, Vishnu YV, Kishan V, et al. Development of nitrendipine transdermal patches: in vitro and ex vivo characterization. Curr Drug Deliv 2007;4:69-76 (Pubitemid 46066416)
53. Tipre DN, Vavia PR. Acrylate-based transdermal therapeutic system of nitrendipine. Drug Dev Ind Pharm 2003;29:71-8 (Pubitemid 36205883)
54. Mittal A, Sara UV, Ali A, et al. The effect of penetration enhancers on permeation kinetics of nitrendipine in two different skin models. Biol Pharm Bull 2008;31:1766-72
55. Ruan LP, Liang BW, Tao JZ, et al. Transdermal absorption of nitrendipine from adhesive patches. J Control Rel 1992;20:231-6
56. Mittal A, Sara UV, Ali A. Formulation and evaluation of monolithic matrix polymer films for transdermal delivery of nitrendipine. Acta Pharm 2009;59:383-93
57. Bhaskar K, Krishna MC, Lingam M, et al. Development of SLN and NLC enriched hydrogels for transdermal delivery of nitrendipine: in vitro and in vivo characteristics. Drug Dev Ind Pharm 2009;35:98-113
58. Bhaskar K, Krishna MC, Lingam M, et al. Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: in vitro and ex vivo characterization. Drug Dev Ind Pharm 2008;34:719-25 (Pubitemid 351962344)
59. Hassan N, Ali M, Ali J. Development and evaluation of novel buccoadhesive wafers of nimodipine for treatment of hypertension. Drug Deliv 2010;17:59-67
60. Hassan N, Ali M, Ali J. Novel buccal adhesive system for anti-hypertensive agent nimodipine. Pharm Dev Technol 2010;15:124-30 . Demonstrates that transbuccal delivery of nimodipine gives encouraging results.
61. Kirch W, Ramsch KD, Dührsen U, et al. Clinical pharmacokinetics of nimodipine in normal and impaired renal function. Int J Clin Pharmacol Res 1984;4:381-4 (Pubitemid 15192673)
62. Kumana CR, Kou M, Yu YL, et al. Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage. Eur J Clin Pharmacol 1993;45:363-6 (Pubitemid 23338547)
63. Krishnaiah YS, Bhaskar P, Satyanarayana V. Formulation and evaluation of limonene-based membranemoderated transdermal therapeutic system of nimodipine. Drug Deliv 2004;11:1-9 (Pubitemid 38292721)
64. Krishnaiah YS, Bhaskar P, Satyanarayana V. In vitro percutaneous permeability enhancement of nimodipine by limonene across the excised rat abdominal skin. Pharmazie 2004;59(12):942-7 (Pubitemid 39664494)
65. Krishnaiah YS, Bhaskar P. Studies on the transdermal delivery of nimodipine from a menthol-based TTS in human volunteers. Curr Drug Deliv 2004;1(2):93-102
66. Giannakou SA, Dallas PP, Rekkas DM, et al. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design. Pharm Dev Technol 1998;3:517-25 (Pubitemid 28530348)
67. Krishnaiah YS, Bhaskar P, Satyanarayana V. Penetration-enhancing effect of ethanol-water solvent system and ethanolic solution of carvone on transdermal permeability of nimodipine from HPMC gel across rat abdominal skin. Pharm Dev Technol 2004;9:63-74 (Pubitemid 38250227)
68. Giannakou SA, Dallas PP, Rekkas DM, et al. In vitro evaluation of nimodipine permeation through human epidermis using response surface methodology. Int J Pharm 2002;241:27-34 (Pubitemid 34667063)
69. Moffat AC, David O, Brian W. Clarke's analysis of drugs and poisons. Pharmaceutical Press, London; 2005
70. Sweetman SC. Martindale: The complete drug reference. Pharmaceutical Press, London, UK; 2005
71. Tirunagari M, Jangala VR, Khagga M, et al. Transdermal therapeutic system of isradipine: effect of hydrophilic and hydrophobic matrix on in vitro and ex vivo characteristics. Arch Pharm Res 2010;33:1025-33
72. Lee CR, Bryson HM. Lacidipine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension. Drugs 1994;48:274-96 (Pubitemid 24260358)
73. Salako BL, Kadiri S, Walker O, et al. Evaluation of lacidipine (a calcium blocker) in the treatment of hypertension in black African people: a double-blind comparison with hydrochlorothiazide. Afr J Med Med Sci 1998;27:73-5
74. McCormack PL, Wagstaff AJ. Lacidipine: a review of its use in the management of hypertension. Drugs 2003;63:2327-56 (Pubitemid 37330535)
75. Gannu R, Palem CR, Yamsani VV, et al. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm 2010;388:231-41 . Indicates that microemulsion based transdermal gel significantly improved bioavailability of dihydropyridine type antihypertensive drug.
76. Saltiel E, Ellrodt AG, Monk JP, et al. Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1998;36:387-428
77. Diez I, Peraire C, Obach R, Domenech J. Influence of d-limonene on the transdermal penetration of felodipine. Eur J Drug Metab Pharmacokinet 1998;23(1):7-12 (Pubitemid 28230319)
78. Wang WG, Yun LH, Wang R, et al. Preparation of transdermal drug delivery system of felodipine-metoprolol and its bioavailability in rabbits. Yao. Xue. Xue. Bao 2007;42:1206-14
79. Trotta M, Morel S, Gasco MR, et al. Effect of oil phase composition on the skin permeation of felodipine from o/w microemulsions. Pharmazie 1997;52:50-3 (Pubitemid 127491519)
80. Williams DM, Cubeddu LX. Amlodipine pharmacokinetics in healthy volunteers. J Clin Pharmacol 1988;28:990-4 (Pubitemid 19013409)
81. Chhabra G, Chuttani K, Mishra AK, et al. Design and development of nanoemulsion drug delivery system of amlodipine besilate for improvement of oral bioavailability. Drug Dev Ind Pharm 2011;37:907-16
82. McDaid DM, Deasy PB. Formulation development of a transdermal drug delivery system for amlodipine base. Int J Pharm 1996;133:71-83 (Pubitemid 26160836)
83. Sun Y, Fang L, Zhu M, et al. A drug-in-adhesive transdermal patch for S-amlodipine free base: in vitro and in vivo characterization. Int J Pharm 2009;382:165-71
84. Zeng A, Wang C, Yuan B, et al. The influence of chirality, physicochemical properties, and permeation enhancers on the transdermal permeation of amlodipine across rat skin. Drug Dev Ind Pharm 2010;36:724-34
85. Jiang Y, Fang L, Niu X, et al. The effect of ion pairing on the skin permeation of amlodipine. Pharmazie 2008;63:356-60 (Pubitemid 351744517)
86. Kumar D, Aqil M, Rizwan M, et al. Investigation of a nanoemulsion as vehicle for transdermal delivery of amlodipine. Pharmazie 2009;64:80-5
87. Paranjothy KLK, Thampi PP. Transdermal drug delivery systems. Indian J Pharm Sci 1997;59:1-4
88. Follath F, Ha HR, Schütz E, et al. Pharmacokinetics of conventional and slow-release verapamil. Br J Clin Pharmacol 1986;21:149S-53S (Pubitemid 17171488)
89. Gungor S, Bektaş A, Alp FI, et al. Matrix-type transdermal patches of verapamil hydrochloride: in vitro permeation studies through excised rat skin and pharmacodynamic evaluation in rats. Pharm Dev Technol 2008;13:283-9
90. Kusum DV, Saisivam S, Maria GR, et al. Design and evaluation of matrix diffusion controlled transdermal patches of verapamil hydrochloride. Drug Dev Ind Pharm 2003;29:495-503 (Pubitemid 36597390)
91. Sekine T, Machida Y, Nagai T. Gel ointment of verapamil for percutaneous absorption. Drug Des Deliv 1987;1:245-52 (Pubitemid 17161576)
92. Shah HS, Tojo K, Chien YW, et al. Transdermal controlled delivery of verapamil: characterization of in vitro skin permeation. Int J Pharm 1992;86:167-73
93. Jain GK, Sharma AK, Agrawal SS. Transdermal controlled administration of verapamil-enhancement of skin permeability. Int J Pharm 1996;130:169-77
94. Mundada AS, Avari JG. In vitro and in vivo characterization of novel biomaterial for transdermal application. Curr Drug Deliv 2011;8(5):517-25
95. Basile J. The role of existing and newer calcium channel blockers in the treatment of hypertension. J Clin Hypertens 2004;6:621-9
96. Mazzo DJ, Obetz CL, Shuster J. Diltiazem hydrochloride. In: Florey K, editor. Analytical profiles of drug substances and excipients. Academic Press; 1994. pp 53-98
97. Gilman AG, Goodman LS, Rall TW, et al. The pharmacological basis of therapeutics. McGraw-Hill, New York; 1996
98. Sweetman SC. Martindale: the complete drug reference. Pharmaceutical Press, London, UK; 2006
99. Rao PR, Diwan PV. Formulation and in vitro evaluation of polymeric films of diltiazem hydrochloride and indomethacin for transdermal administration. Drug Dev Ind Pharm 1998;24:327-36 (Pubitemid 28204501)
100. Rao PR, Diwan PV. Comparative in vivo evaluation of diltiazem hydrochloride following oral and transdermal administration in rabbits. Indian J Pharmacol 1999;31:294-8 . Demonstrates that transdermal delivery of an antihypertensive drug gives encouraging results. (Pubitemid 29416777)
101. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal patches based on povidone-ethylcellulose matrices. Drug Dev Ind Pharm 2003;29:1-7 (Pubitemid 36205876)
102. Jain SK, Chourasia MK, Sabitha M, et al. Development and characterization of transdermal drug delivery systems for diltiazem hydrochloride. Drug Deliv 2003;10:169-77 (Pubitemid 36993368)
103. Mundada AS, Avari JG. Novel biomaterial for transdermal application: in vitro and in vivo characterization. Drug Deliv 2011;18(6):424-31
104. Mundada AS, Avari JG. Permeability studies of damar batu free films for transdermal application. Chem Ind & Chem Eng Quart 2009;15(2):83-8
105. Limpongsa E, Umprayn K. Preparation and evaluation of diltiazem hydrochloride diffusion-controlled transdermal delivery system. AAPS PharmSciTech 2008;9:464-70
106. Karakatsani M, Dedhiya M, Plakogiannis FM. The effect of permeation enhancers on the viscosity and the release profile of transdermal hydroxypropylmethylcellulose gel formulations containing diltiazem HCl. Drug Dev Ind Pharm 2010;36(10):1195-206
107. Fulzele SV, Satturwar PM, Dorle AK. Polymerized rosin: novel film forming polymer for drug delivery. Int J Pharm 2002;249:175-84 (Pubitemid 35333444)
108. Satturwar PM, Fulzele SV, Dorle AK. Evaluation of polymerized rosin for the formulation and development of transdermal drug delivery system: a technical note. AAPS PharmSciTech 2005;6:E649-54
109. Silva SM, Hu L, Sousa JJ, et al. A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl. Eur J Pharm Biopharm 2012;80:663-73